Early identification and treatment of patients with COPD at risk of exacerbation are crucial for better outcomes. Single-inhaler triple therapy (SITT) users showed improved exacerbation rates and ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the world’s first low-carbon version of a triple-combination inhaler for chronic obstructive pulmonary disease (COPD). The ...
While the effectiveness of drug therapy for COPD patients at advanced stages of disease has been proven, little evidence exists regarding starting treatment at earlier stages. The findings of the ...
Claims data analysis showed that 60% of patients with chronic obstructive pulmonary disease (COPD) receiving triple therapy had no evidence of exacerbation or only 1 exacerbation not resulting in ...
This article is developed and funded by Chiesi Ltd. Dr Sooj has been paid an honorarium for his author contribution. Views are the author’s own and do not represent the NHS. I’M Dr Suraj Kukadia, ...
New york, USA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight ...
Every 30 seconds, someone in the world will experience a flare-up of their asthma or chronic obstructive pulmonary disease (COPD) symptoms. For decades, the standard treatment for these potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results